

Deletion of MORpholino Binding Sites (DeMOBS) to Assess Specificity of Morphant Phenotypes

Carlee MacPherson Cunningham, Gianfranco Bellipanni, Raymond Habas and Darius
Balciunas*

Department of Biology, College of Science and Technology, Temple University,
Philadelphia, PA 19122, USA

* correspondence to darius@temple.edu

Abstract

Two complimentary approaches are widely used to study gene function in zebrafish: induction of genetic mutations, usually using targeted nucleases such as CRISPR/Cas9, and suppression of gene expression, typically using Morpholino oligomers. Neither method is perfect. Morpholinos (MOs) sometimes produce off-target or toxicity-related effects that can be mistaken for true phenotypes. Conversely, genetic mutants can be subject to compensation, or may fail to yield a null phenotype due to leakiness. When discrepancy between mutant and morpholino-induced (morphant) phenotypes is observed, experimental validation of such phenotypes becomes very labor intensive. We have developed a simple genetic method to differentiate between genuine morphant phenotypes and those produced due to off-target effects. We speculated that indels within 5' untranslated regions would be unlikely to have a significant negative effect on gene expression. Mutations induced within a MO target site would result in a Morpholino-refractive allele thus suppressing true MO phenotypes whilst non-specific phenotypes would remain. We tested this hypothesis on one gene with an exclusively zygotic function, *tbx5a*, and one gene with strong maternal effect, *ctnnb2*. We found that indels within the Morpholino binding site are indeed able to suppress both zygotic and maternal morphant phenotypes. We also observed that the ability of such indels to suppress Morpholino phenotypes does depend on the size and the location of the deletion. Nonetheless, mutating the morpholino binding sites in both maternal and zygotic genes can ascertain the specificity of morphant phenotypes.

Introduction

Methods used to analyze gene loss-of-function fall into two categories: “knockout”, which aims to inactivate the gene of interest by introducing mutations using techniques such as CRISPR/Cas9, and “knockdown”, which aims to abrogate the expression of the gene of interest by employing methods such as siRNA, CRISPRi or Morpholino oligomers (for a recent review, see (Housden et al., 2017)).

Morpholino oligomers are the most widely used antisense knockdown technology in the zebrafish (Egger and Larson, 2001; Nasevicius and Egger, 2000). They inhibit gene expression by blocking either translation or splicing. Translation-blocking MOs base pair with the mRNA at or upstream of the translation start site and prevent assembly of the 80S ribosome. They inhibit expression of both zygotic and maternally deposited mRNAs and can be used to phenocopy maternal-zygotic mutants. Splice-blocking MOs bind to pre-mRNA at either the splice acceptor or the splice donor site and prevent assembly of the spliceosome, thus abrogating expression of zygotic transcripts but having no effect on maternally deposited mature mRNAs. MO technology, however, suffers from a significant drawback: off-target effects. Some off-target effects caused by activation of the p53 pathway can be suppressed by co-injection of a standard MO targeting p53 (Robu et al., 2007). Nonetheless, presence of off-target effects necessitates thorough and labor-intensive validation of morphant phenotypes, including mRNA rescue and use of multiple MOs targeting the gene of interest (Eisen and Smith, 2008; Stainier et al., 2017).

It is not uncommon for knockdown- and knockout-based approaches to yield different results (Bachas et al., 2018; Evers et al., 2016; Luttrell et al., 2018; Morgens et al., 2016). Such discrepancies have also been observed in zebrafish (Joris et al., 2017; Kok et al., 2015; Law and Sargent, 2014; Novodvorsky et al., 2015; Rossi et al., 2015). Sometimes they can be attributed to built-in shortcomings of each approach. Small indels do not always result in complete loss-of-function: a variety of phenomena including splicing artifacts and translation initiation at a downstream AUGs and may lead to production of a functional protein, masking the null phenotype (Anderson et al., 2017; Lalonde et al., 2017; Smits et al., 2019). A further

complication in the analysis of mutant phenotypes arises from the fact that for some genes, maternally-deposited mRNAs partly mask mutant phenotypes necessitating the use of maternal-zygotic mutants (Gritsman et al., 1999; Miller-Bertoglio et al., 1999). Additionally, some frameshift and nonsense mutants induce transcriptional compensation by closely related genes (El-Brolosy et al., 2019; Ma et al., 2019; Rossi et al., 2015). Deleting the whole coding sequence appears to be the best way to eliminate these possibilities. However, regulatory complexity of vertebrate genomes raises the possibility the observed phenotype may be caused deletion of intron-residing *cis*-regulatory elements for other genes (for an example, see (Zhou et al., 2009; Zuniga et al., 2012)).

With the notable exception of short upstream reading frames (Johnstone et al., 2016), 5' UTRs appear to be sparse in significant regulatory features. We speculated that indel mutations within 5' UTRs are unlikely to significantly impair the expression of the downstream gene (Burg et al., 2018). Introduced indels within a morpholino target site should reduce, if not entirely abolish, MO binding making the “mutant mRNA” partly or completely refractive to morpholino binding. We further hypothesized that since few genes are haploinsufficient, heterozygosity for such MO-refractive mutations would be sufficient to suppress specific morpholino phenotypes. Using *tbx5a* and *ctnnb2* as test loci, we demonstrate that deletions can be readily generated and used to test the specificity of both zygotic and maternal morphant phenotypes.

Results and Discussion

Partial suppression of *tbx5a* morphant phenotypes by the (-7) mutation in MO target site

Tbx5a mutants and morphants display absent or malformed pectoral fins and a linear heart (**Figure 1A**) (Ahn et al., 2002; Garrity et al., 2002; Grajevskaja et al., 2018; Ng et al., 2002). Since *tbx5a* mRNA is not contributed maternally, outcross of a

parent heterozygous for a potentially MO-refractive mutation would produce a clutch of embryos where half would be genotypically wild type and susceptible to the MO, while the other half would be “mutant” and thus refractive to the MO. Susceptible and refractive embryos, present within a single clutch, would serve as controls for each other, eliminating experimental bias by excluding variables such as active MO concentration, injection volume or timing of the injection.

Two *S. pyogenes* PAM sites are present within the 5'UTR sequence targeted by *tbx5a*-MO4 (Lu et al., 2008) (**Figure 1B**). We synthesized 19-base guide RNAs with a G nucleotide (lower case in **Figure 1B**) required for transcription initiation by the T7 RNA polymerase added, and injected them along with nCas9n mRNA as previously described (Burg et al., 2018; Burg et al., 2016). PCR fragments amplified on lysates from 20 pooled 3 day post fertilization (dpf) injected embryos were analyzed for sgRNA efficiency by TIDE (Brinkman et al., 2014) and Synthego ICE (Hsiau et al., 2019). Both analyses showed that *tbx5ade*MO2 sgRNA (~30% by TIDE, ~11% by ICE) was more efficient than *tbx5ade*MO1 sgRNA (~17% by TIDE, 7% by ICE) (**Supplemental Figure 1A**). We raised embryos injected with *tbx5ade*MO2 sgRNA and nCas9n and screened three F0 fish for germline transmission of indels using the T7 endonuclease assay (data not shown). One founder produced a high percentage of progeny with indels, and one F1 family was raised. Four out of seven genotyped adult F1s were found to be heterozygous for indels: two for a (-3) deletion and two for a (-7) deletion by Poly Peak Parser (Hill et al., 2014) analysis. F1s heterozygous for (-3) and (-7) deletions were incrossed. All embryos were phenotypically normal, indicating that these deletions do not significantly impair the expression of *tbx5a*. Sequence of the (-3) and (-7) deletions was confirmed on homozygous F2s (**Figure 1C**).

To determine the effective dose of *Tbx5a*-MO4, we injected 2, 4, 8 and 12 ng of the morpholino into one-cell zebrafish embryos (**Figure 1D**). The lowest dose of the MO resulted in >90% of embryos displaying pectoral fin defects. In contrast, a much higher 8 ng dose of the MO was needed to elicit severe cardiac defects (>90% edema). Notably, in humans suffering from Holt-Oram syndrome caused by

mutations in *Tbx5*, forelimb defects are also more penetrant and severe than cardiac defects (Basson et al., 1997; Basson et al., 1994; Smith et al., 1979).

We outcrossed F1 fish heterozygous for the (-3) and (-7) deletions and injected embryos with 2 ng or 8 ng *Tbx5a*-MO4. In each cross, approximately 50% of embryos were expected to be genetically wild type and therefore display morphant phenotypes, while the other 50% were expected to inherit the corresponding deletion, leading to either partial or complete suppression of MO phenotypes. At the low 2 ng MO dose, 12/38 (32%) of embryos from the (-3) heterozygote outcross were phenotypically wild type, whilst 10/38 (26%) showed the milder pectoral fin defect phenotype, indicating full or partial rescue in approximately 50% of the progeny as expected. Among embryos from the (-7) heterozygote outcross, 20/35 (57%) showed full rescue of both the cardiac edema and pectoral fin loss phenotype (**Figure 1E**). Embryos from both outcrosses were grouped by phenotype and genotyped. In the (-3) outcross, genotyping revealed that 6/8 (75%) embryos displaying pectoral fin loss or defects were wild-type, and 7/8 (88%) phenotypically wild-type embryos were heterozygous for the (-3) deletion ($P = .015$). In the (-7) outcross, genotyping revealed that 8/8 (100%) embryos displaying pectoral fin loss or defects were wild-type, and 7/8 (88%) phenotypically wild-type embryos were heterozygous for the (-7) deletion ($P = .002$). These results confirmed that at a low dose of the morpholino, the (-3) allele can largely suppress the morphant phenotype while the (-7) allele shows complete rescue.

At the high 8 ng MO dose, all MO-injected embryos from the (-3) outcrosses displayed identical morphant phenotypes (**Figure 1E**). In contrast, approximately 50% of embryos from the (-7) outcross were completely rescued from the cardiac edema phenotype, but not the pectoral fin defect (**Figure 1E**). Embryos from the (-7) outcross were grouped by phenotype and subsequently genotyped. Genotyping revealed that 14/15 (93%) of individuals with cardiac edema and loss of pectoral fins were wild-type and 13/16 (81%) of individuals with no cardiac edema were heterozygous for the (-7) allele ($P=3.0E-05$) (data not shown). These results indicate rescue of cardiac edema morphant phenotype, but not the pectoral fin phenotype, by heterozygosity for the (-7) allele at the high dose of the Morpholino.

Dose-, phenotype- and deletion size-dependent rescue of morphant phenotypes prompted us to hypothesize that (-3) and (-7) deletions were insufficient to make mRNAs entirely refractive to the morpholino. We cloned wild type, (-3) and (-7) target sites into the pT3TS *in vitro* transcription vector (Hyatt and Ekker, 1999) ahead of eGFP coding sequence. *In vitro* transcribed mRNAs were injected into embryos along with pT3TS:mRFP mRNA as a control not affected by the MO. Half of the mRNA-injected embryos were then injected with 8 ng of Tbx5a-MO4. Embryos were scored for RFP and GFP fluorescence and photographed at 1 dpf (**Figure 1F**). We found that Tbx5a-MO4 was able to almost entirely block translation of mRNAs containing wild type and (-3) target sites. Translation of mRNA containing the (-7) target site was also reduced significantly (**Figure 1F**). These findings raise significant concerns about MO specificity. The (-3) and (-7) deletions preserved a 16-nucleotide and 15-nucleotide identity to the target site at the 3' end of the MO (toward the 5' end of the mRNA), respectively. Our data therefore indicate that a 3' stretch of identity as short 15-16 nucleotides may be sufficient for a MO to impede translation at a high dose, and suggests that using MOs shorter than the current 25 nucleotide standard may lead to higher specificity.

Suppression of the *b-catenin* morphant phenotype by maternal contribution of (-4) binding site mutant *ctnnb2* mRNA

We speculated that for maternally contributed genes, a female heterozygous for a MO-refractive allele would produce embryos which would be refractive to the maternal-zygotic phenotype. To test this hypothesis, we selected beta-catenin genes coding for an essential component of the Wnt signaling pathway. Co-injection of translation-blocking MOs targeting the duplicated *ctnnb1* and *ctnnb2* mRNAs results in complete loss of ventral cell fates and a phenotype named *ciuffo* (Bellipanni et al., 2006). Partial sequencing of *ctnnb2* loci in the TLF genetic background revealed presence of a single nucleotide polymorphism within the *ctnnb2*-MO1 binding site. Co-injection of *ctnnb1*-MO2 and *ctnnb2*-MO1 into TLF embryos at concentrations described previously (Bellipanni et al., 2006) resulted in nearly 100% penetrant

ciuffo phenotype (data not shown), indicating the polymorphism alone does not appreciably reduce morpholino activity.

Two sgRNAs targeting PAM sequences within the *ctnnb2*-MO1 binding site were designed and tested (**Figure 2A**). Only *ctnnb2deMO1* had detectable activity by both TIDE (~17%) and Synthego ICE (~5%) analysis (**Supplementary Figure 2**). Three adult F0 fish injected with *ctnnb2deMO1* sgRNA and nCas9n mRNA were tested for germline transmission of indels, leading to establishment of one F1 family. Fourteen F1 fish were tested for loss of Bpu10I restriction enzyme site, and seven were found to be heterozygous for indels. PCR fragments from five F1s were sequenced, and four were found to be heterozygous for a (-4) deletion (**Figure 2B**). A male heterozygous for the (-4) deletion was outcrossed to establish an F2 family.

To avoid experimental bias, we performed a blind experiment to test for suppression of *ciuffo* phenotype. From a single F2 family, we identified two adult females heterozygous for the deletion and two wild type siblings. Fish were coded A, B, C and D, and embryos obtained from outcrosses were injected with a mixture of *ctnnb1*-MO2 and *ctnnb2*-MO1. MO injection lead to high penetrance (89% and 100%) of *ciuffo* phenotypes in the progeny of wild type fish, while presence of one (-4) allele in heterozygotes almost completely suppressed the *ciuffo* phenotype (4% and 13%, **Figure 2C**). Milder phenotypes were still observed in a subset of embryos, which could reflect zygotic requirement for *ctnnb1* and/or *ctnnb2* (Valenti et al., 2015; Varga et al., 2007), or off-target effects due to a high cumulative dose of the two MOs. Nonetheless, the observation that females heterozygous for a (-4) deletion in combination with a serendipitous single nucleotide polymorphism produce embryos which are nearly 100% suppressed for the *ciuffo* phenotype indicates that out method can be used to ascertain morphant phenotypes of genes with strong maternal contribution of mRNA.

Our data clearly demonstrates that indels within MO binding sites can be readily generated and used to test the specificity of both zygotic and maternal morphant phenotypes. The ability to induce deletions within MO binding sites using CRISPR/Cas9 relies on the presence of a PAM site within the MO binding site, preferably close to the 5' end of the target site. While the mutagenesis method

employed by us is likely feasible for the majority of MOs targeting 5' UTRs, there will inevitably be a subset where PAM sites will be absent or located closer to the middle or the 3' of the target site. In such cases, oligonucleotide-mediated repair of double strand breaks can be used to engineer desired mutations (Bedell et al., 2012; Burg et al., 2018; Burg et al., 2016; Dong et al., 2014; Gagnon et al., 2014; Gibb et al., 2018; Hruscha et al., 2013; Prykhozhij et al., 2018).

Materials and Methods

CRISPR/Cas9 mutagenesis

Guide RNAs were produced as previously described (Burg et al., 2018; Burg et al., 2016) using DR274 (Hwang et al., 2013) as the template and diluted to ~60 ng/ μ L. Immediately prior to injection, 8 μ L of diluted sgRNA was mixed with 2 μ L aliquot of 150 ng/ μ L nCas9n mRNA (Jao et al., 2013) to the final volume of 10 μ L.

Plasmid construction and mRNA synthesis

Details of plasmid construction are available upon request. eGFP-containing pT3TS (Hyatt and Ekker, 1999) vectors (pCMC23 (wt MO binding site), pCMC24 (-3) and pCMC25 (-7)) were linearized using XbaI restriction enzyme. Template for the synthesis of mRFP mRNA was amplified by PCR using M13F/M13R primer pair on pT3TS:mRFP (pDB935). Templates were transcribed using T3 mMessage mMachine kit and mRNAs were purified using Qiagen RNeasy MinElute kit. mRNAs were diluted so that the standard 3 nL injection volume would contain 50 ng of *tbx5a*-eGFP mRNA and 100 ng of mRFP mRNA.

Microinjection

Microinjection volumes were calibrated to 3 nL as previously described, and all microinjections were performed into the yolks of 1-cell zebrafish embryos as described (Balciuniene and Balciunas, 2013).

Figure Legends

Figure 1. Partial rescue of *Tbx5a*-MO4 morphant phenotype by (-3) and (-7) binding site mutations. (A) Embryos injected with *Tbx5a*-MO4 display a range of *tbx5a* loss

of function phenotypes including pectoral fin malformation or absence and severe cardiac edema. Black arrow denotes cardiac edema, black arrowheads denote pectoral fin loss, red arrowheads denote pectoral fin defects. (PFA+E, pectoral fins absent with edema, PFD+E, pectoral fin defect with edema, PFD, pectoral fin defect only) (B) Two sgRNAs, *tbx5adeM01* and *tbx5adeM02* targeting the *tbx5a-M04* binding site (MO sequence shown above in purple, PAM sites are highlighted in magenta, coding sequence is highlighted in green. *Tbx5adeM02* overlaps a *RsaI* restriction enzyme site used for genotyping. (C) Sequence confirmation of the (-3) and (-7) deletion alleles. (D) Titration of *Tbx5a-M04* in wild type (TFL) embryos. Numbers indicate percentages of embryos displaying designated morphant phenotypes. WT is wild-type, E is edema only. (E) Suppression of cardiac and/or pectoral fin phenotypes by the (-3) and (-7) binding site deletions at different doses of MO. Adults heterozygous for either the (-3) or (-7) deletion were outcrossed and embryos were injected with either 2 ng or 8 ng of *tbx5a-M04*. (F) *Tbx5a-M04* is able to at least partly block the translation of mRNAs containing (-3) and (-7) binding site mutations. *In vitro* transcribed mRNAs from each eGFP construct was injected along with mRFP mRNA as a control, and half of the mRNA-injected embryos were then injected with *tbx5a-M04*. At 1dpf, embryos displaying similar levels of mRFP expression were photographed. T3, T3 transcription start site, X β g 5' UTR and X β g 3' UTR, *Xenopus* β -globin 5' and 3' untranslated regions, respectively.

Figure 2. Suppression of a maternal morphant phenotype by DeMOBS. (A) Two sgRNAs, *ctnnb2deM01* and *ctnnb2deM02* target *ctnnb2-M01* binding site. *ctnnb2deM01* overlaps a *Bpu10I* restriction enzyme site used for genotyping. A single nucleotide polymorphism resulting in a single base mismatch between the MO and the target sequence is shown in lower case. (B) Confirmation of the (-4) allele by sequence analysis. (C) Co-injection *ctnnb2-M01* and *ctnnb1-M02* into embryos obtained from four female siblings (two wild type and two heterozygous for the deletion) in blind experiments. (D) *ciuffo* morphant phenotype resulting from injection of *ctnnb1-M02* and *ctnnb2-M01*. (E-H) Residual phenotypes

observed in MO-injected embryos from a female heterozygous for the MO-refractive (-4) mutation.

Supp. Figure 1. Testing the efficiency of *tbx5adeMO1* or *tbx5adeMO2* sgRNAs by sequencing. Targeted locus was amplified with primers *tbx5ain1-F2* and *tbx5aex2-R2*, using lysate of 20 pooled embryos as the template. PCR fragments were sequenced using *tbx5aex2-R2*. (A) Sequencing of embryos injected with *tbx5adeMO1*. Please note that reverse complement of sequencing chromatogram is provided to correspond to Figure 1B. The expected location of the double strand break is indicated by the red arrow. (B) Sequencing of embryos injected with *tbx5adeMO2*. (C) Efficiency of the two guides and most prevalent deletions as estimated by TIDE (<https://tide.deskgen.com/>) and Synthego ICE (<https://ice.synthego.com/#/>).

Supp. Figure 2. Testing the efficiency of *ctnnb2deMO1* or *ctnnb2deMO2* guide RNAs by sequencing. Targeted locus was amplified with primers *ctnnb2-F1* and *ctnnb2-R1*, using lysate of 20 pooled embryos as the template, and the obtained PCR fragments were sequenced using *ctnnb2-F1*. (A) Sequencing of embryos injected with *ctnnb2deMO1*. The expected location of the double strand break is indicated by the red arrow. (B) Sequencing of embryos injected with *ctnnb2deMO2*. (C) Efficiency of the two guides and most prevalent deletions as estimated by TIDE (<https://tide.deskgen.com/>) and Synthego ICE (<https://ice.synthego.com/#/>).

Supplementary Table 1. Primer sequences

Primer	Sequence 5' to 3'
Genotyping primers	
<i>tbx5ain1-F2</i>	CAGATTCATGAACTATCGGTGTACA
<i>tbx5aex2-R2</i>	CTGTTGAATGTATGTAGTCTGCGAT
<i>ctnnb2-F1</i>	CTGGCAATTCCTAATGACTCAGTCT
<i>ctnnb2-R1</i>	AGCCTATAGCGATAAGCTAAATCAC
Specific primers used for guide RNA synthesis	
<i>tbx5adeMO1</i>	CGCTAGCTAATACGACTCACTATAGCTGTACGATGCTACCGTGGTTTGTAGAGCTAGAAATAG
<i>tbx5adeMO2</i>	CGCTAGCTAATACGACTCACTATAGCTCAGGTAGACATCGTACGTTTGTAGAGCTAGAAATAG
<i>ctnnb2deMO1</i>	CGCTAGCTAATACGACTCACTATAGCAGGTTTGAAAGTCGCTCGTTTGTAGAGCTAGAAATAG

ctnnb2deMO2	CGCTAGCTAATACGACTCACTATAG GAAAGTCGCTCAGGCTAAG TTTTAGAGCTAGAAATAG
Universal primers used for guide RNA synthesis (Burg et al., 2016)	
sgT7	GCTAGCTAATACGACTCACT
sgRNA-R	AAAAGCACCGACTCGGTG
M13F	GTAAACGACGGCCAGT
Primers used to clone MO4-Tbx5a binding site	
Yellow highlight: <i>tbx5a</i> 5' UTR sequence	
Bold: MO4-Tbx5a binding site	
Green highlight: eGFP coding sequence	
tbx5aeGFP-F1	ttagatct GCCTCACGGTAGACATCGTACAGGCCTCTCCGAC ggatcc atggtgagcaagggcg
tbx5aeGFP-F2	ttagatct GCCTCACGGTAGACA --- TACAGGCCTCTCCGAC ggatcc atggtgagcaagggcg
tbx5aeGFP-F3	ttagatct GCCTCACGGTAGACA ----- GCCTCTCCGAC ggatcc atggtgagcaagggcg

Supplementary Table 2. Sequences of Morpholino oligomers.

MO (based on zfin.org)	Sequence 5' to 3'	Reference
tbx5a-MO4	GCCTGTACGATGTCTACCGTGAGGC	tbx5-MO2 in Lu et al., 2008
ctnnb1-MO2	CTGGGTAGCCATGATTTTCTCACAG	β -catenin-1 MO1 in Bellipanni et al., 2006
ctnnb2-MO1	CCTTTAGCCTGAGCGACTTCCAAC	β -catenin-2 MO2 in Bellipanni et al., 2006

References


- Ahn, D.G., Kourakis, M.J., Rohde, L.A., Silver, L.M., Ho, R.K., 2002. T-box gene *tbx5* is essential for formation of the pectoral limb bud. *Nature* 417, 754-758.
- Anderson, J.L., Mulligan, T.S., Shen, M.C., Wang, H., Scahill, C.M., Tan, F.J., Du, S.J., Busch-Nentwich, E.M., Farber, S.A., 2017. mRNA processing in mutant zebrafish lines generated by chemical and CRISPR-mediated mutagenesis produces unexpected transcripts that escape nonsense-mediated decay. *PLoS Genet* 13, e1007105.
- Bachas, C., Hodzic, J., van der Mij, J.C., Stoepker, C., Verheul, H.M.W., Wolthuis, R.M.F., Felley-Bosco, E., van Wieringen, W.N., van Beusechem, V.W., Brakenhoff, R.H., de Menezes, R.X., 2018. Rscreenorm: normalization of CRISPR and siRNA screen data for more reproducible hit selection. *BMC Bioinformatics* 19, 301.
- Balciuniene, J., Balciunas, D., 2013. Gene trapping using *gal4* in zebrafish. *J Vis Exp*, e50113.
- Basson, C.T., Bachinsky, D.R., Lin, R.C., Levi, T., Elkins, J.A., Soult, J., Grayzel, D., Kroumpouzou, E., Traill, T.A., Leblanc-Straceski, J., Renault, B., Kucherlapati, R., Seidman, J.G., Seidman, C.E., 1997. Mutations in human *TBX5* [corrected] cause limb and cardiac malformation in Holt-Oram syndrome. *Nat Genet* 15, 30-35.
- Basson, C.T., Cowley, G.S., Solomon, S.D., Weissman, B., Poznanski, A.K., Traill, T.A., Seidman, J.G., Seidman, C.E., 1994. The clinical and genetic spectrum of the Holt-Oram syndrome (heart-hand syndrome). *N Engl J Med* 330, 885-891.
- Bedell, V.M., Wang, Y., Campbell, J.M., Poshusta, T.L., Starker, C.G., Krug, R.G., 2nd, Tan, W., Penheiter, S.G., Ma, A.C., Leung, A.Y., Fahrenkrug, S.C., Carlson, D.F., Voytas, D.F., Clark, K.J., Essner, J.J., Ekker, S.C., 2012. In vivo genome editing using a high-efficiency TALEN system. *Nature* 491, 114-118.
- Bellipanni, G., Varga, M., Maegawa, S., Imai, Y., Kelly, C., Myers, A.P., Chu, F., Talbot, W.S., Weinberg, E.S., 2006. Essential and opposing roles of zebrafish beta-catenins in the formation of dorsal axial structures and neurectoderm. *Development* 133, 1299-1309.
- Brinkman, E.K., Chen, T., Amendola, M., van Steensel, B., 2014. Easy quantitative assessment of genome editing by sequence trace decomposition. *Nucleic Acids Res* 42, e168.
- Burg, L., Palmer, N., Kikhi, K., Miroshnik, E.S., Rueckert, H., Gaddy, E., MacPherson Cunningham, C., Mattonet, K., Lai, S.L., Marin-Juez, R., Waring, R.B., Stainier, D.Y.R., Balciunas, D., 2018. Conditional mutagenesis by oligonucleotide-mediated integration of loxP sites in zebrafish. *PLoS Genet* 14, e1007754.
- Burg, L., Zhang, K., Bonawitz, T., Grajevskaja, V., Bellipanni, G., Waring, R., Balciunas, D., 2016. Internal epitope tagging informed by relative lack of sequence conservation. *Sci Rep* 6, 36986.
- Dong, Z., Dong, X., Jia, W., Cao, S., Zhao, Q., 2014. Improving the efficiency for generation of genome-edited zebrafish by labeling primordial germ cells. *Int J Biochem Cell Biol* 55, 329-334.
- Eisen, J.S., Smith, J.C., 2008. Controlling morpholino experiments: don't stop making antisense. *Development* 135, 1735-1743.

- Ekker, S.C., Larson, J.D., 2001. Morphant technology in model developmental systems. *Genesis* 30, 89-93.
- El-Brolosy, M.A., Kontarakis, Z., Rossi, A., Kuenne, C., Gunther, S., Fukuda, N., Kikhi, K., Boezio, G.L.M., Takacs, C.M., Lai, S.L., Fukuda, R., Gerri, C., Giraldez, A.J., Stainier, D.Y.R., 2019. Genetic compensation triggered by mutant mRNA degradation. *Nature* 568, 193-197.
- Evers, B., Jastrzebski, K., Heijmans, J.P., Grernrum, W., Beijersbergen, R.L., Bernardis, R., 2016. CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes. *Nat Biotechnol* 34, 631-633.
- Gagnon, J.A., Valen, E., Thyme, S.B., Huang, P., Ahkmetova, L., Pauli, A., Montague, T.G., Zimmerman, S., Richter, C., Schier, A.F., 2014. Efficient mutagenesis by Cas9 protein-mediated oligonucleotide insertion and large-scale assessment of single-guide RNAs. *PLoS One* 9, e98186.
- Garrity, D.M., Childs, S., Fishman, M.C., 2002. The heartstrings mutation in zebrafish causes heart/fin Tbx5 deficiency syndrome. *Development* 129, 4635-4645.
- Gibb, N., Lazic, S., Yuan, X., Deshwar, A.R., Leslie, M., Wilson, M.D., Scott, I.C., 2018. Hey2 regulates the size of the cardiac progenitor pool during vertebrate heart development. *Development* 145, dev167510.
- Grajevskaja, V., Camerota, D., Bellipanni, G., Balciuniene, J., Balciunas, D., 2018. Analysis of a conditional gene trap reveals that tbx5a is required for heart regeneration in zebrafish. *PLoS One* 13, e0197293.
- Gritsman, K., Zhang, J., Cheng, S., Heckscher, E., Talbot, W.S., Schier, A.F., 1999. The EGF-CFC protein one-eyed pinhead is essential for nodal signaling. *Cell* 97, 121-132.
- Hill, J.T., Demarest, B.L., Bisgrove, B.W., Su, Y.C., Smith, M., Yost, H.J., 2014. Poly peak parser: Method and software for identification of unknown indels using sanger sequencing of polymerase chain reaction products. *Dev Dyn* 243, 1632-1636.
- Housden, B.E., Muhar, M., Gemberling, M., Gersbach, C.A., Stainier, D.Y., Seydoux, G., Mohr, S.E., Zuber, J., Perrimon, N., 2017. Loss-of-function genetic tools for animal models: cross-species and cross-platform differences. *Nat Rev Genet* 18, 24-40.
- Hruscha, A., Krawitz, P., Rechenberg, A., Heinrich, V., Hecht, J., Haass, C., Schmid, B., 2013. Efficient CRISPR/Cas9 genome editing with low off-target effects in zebrafish. *Development* 140, 4982-4987.
- Hsiao, T., Conant, D., Rossi, N., Maures, T., Waite, K., Yang, J., Joshi, S., Kelso, R., Holden, K., Enzmann, B.L., Stoner, R., 2019. Inference of CRISPR Edits from Sanger Trace Data. *bioRxiv*.
- Hwang, W.Y., Fu, Y., Reyon, D., Maeder, M.L., Tsai, S.Q., Sander, J.D., Peterson, R.T., Yeh, J.R., Joung, J.K., 2013. Efficient genome editing in zebrafish using a CRISPR-Cas system. *Nat Biotechnol* 31, 227-229.
- Hyatt, T.M., Ekker, S.C., 1999. Vectors and techniques for ectopic gene expression in zebrafish. *Methods Cell Biol* 59, 117-126.
- Jao, L.E., Wente, S.R., Chen, W.B., 2013. Efficient multiplex biallelic zebrafish genome editing using a CRISPR nuclease system. *Proceedings of the National Academy of Sciences of the United States of America* 110, 13904-13909.
- Johnstone, T.G., Bazzini, A.A., Giraldez, A.J., 2016. Upstream ORFs are prevalent translational repressors in vertebrates. *EMBO J* 35, 706-723.


- Joris, M., Schloesser, M., Baurain, D., Hanikenne, M., Muller, M., Motte, P., 2017. Number of inadvertent RNA targets for morpholino knockdown in *Danio rerio* is largely underestimated: evidence from the study of Ser/Arg-rich splicing factors. *Nucleic Acids Res* 45, 9547-9557.
- Kok, F.O., Shin, M., Ni, C.W., Gupta, A., Grosse, A.S., van Impel, A., Kirchmaier, B.C., Peterson-Maduro, J., Kourkoulis, G., Male, I., DeSantis, D.F., Sheppard-Tindell, S., Ebarasi, L., Betsholtz, C., Schulte-Merker, S., Wolfe, S.A., Lawson, N.D., 2015. Reverse genetic screening reveals poor correlation between morpholino-induced and mutant phenotypes in zebrafish. *Dev Cell* 32, 97-108.
- Lalonde, S., Stone, O.A., Lessard, S., Lavertu, A., Desjardins, J., Beaudoin, M., Rivas, M., Stainier, D.Y.R., Lettre, G., 2017. Frameshift indels introduced by genome editing can lead to in-frame exon skipping. *PLoS One* 12, e0178700.
- Law, S.H., Sargent, T.D., 2014. The serine-threonine protein kinase PAK4 is dispensable in zebrafish: identification of a morpholino-generated pseudophenotype. *PLoS One* 9, e100268.
- Lu, J.H., Lu, J.K., Choo, S.L., Li, Y.C., Yeh, H.W., Shiue, J.F., Yeh, V.C., 2008. Cascade effect of cardiac myogenesis gene expression during cardiac looping in *tbx5* knockdown zebrafish embryos. *J Biomed Sci* 15, 779-787.
- Luttrell, L.M., Wang, J., Plouffe, B., Smith, J.S., Yamani, L., Kaur, S., Jean-Charles, P.Y., Gauthier, C., Lee, M.H., Pani, B., Kim, J., Ahn, S., Rajagopal, S., Reiter, E., Bouvier, M., Shenoy, S.K., Laporte, S.A., Rockman, H.A., Lefkowitz, R.J., 2018. Manifold roles of beta-arrestins in GPCR signaling elucidated with siRNA and CRISPR/Cas9. *Sci Signal* 11.
- Ma, Z., Zhu, P., Shi, H., Guo, L., Zhang, Q., Chen, Y., Chen, S., Zhang, Z., Peng, J., Chen, J., 2019. PTC-bearing mRNA elicits a genetic compensation response via Upf3a and COMPASS components. *Nature* 568, 259-263.
- Miller-Bertoglio, V., Carmany-Rampey, A., Furthauer, M., Gonzalez, E.M., Thisse, C., Thisse, B., Halpern, M.E., Solnica-Krezel, L., 1999. Maternal and zygotic activity of the zebrafish *ogon* locus antagonizes BMP signaling. *Dev Biol* 214, 72-86.
- Morgens, D.W., Deans, R.M., Li, A., Bassik, M.C., 2016. Systematic comparison of CRISPR/Cas9 and RNAi screens for essential genes. *Nat Biotechnol* 34, 634-636.
- Nasevicius, A., Ekker, S.C., 2000. Effective targeted gene 'knockdown' in zebrafish. *Nat Genet* 26, 216-220.
- Ng, J.K., Kawakami, Y., Buscher, D., Raya, A., Itoh, T., Koth, C.M., Rodriguez Esteban, C., Rodriguez-Leon, J., Garrity, D.M., Fishman, M.C., Izpisua Belmonte, J.C., 2002. The limb identity gene *Tbx5* promotes limb initiation by interacting with *Wnt2b* and *Fgf10*. *Development* 129, 5161-5170.
- Novodvorsky, P., Watson, O., Gray, C., Wilkinson, R.N., Reeve, S., Smythe, C., Beniston, R., Plant, K., Maguire, R., A, M.K.R., Elworthy, S., van Eeden, F.J., Chico, T.J., 2015. *klf2ash317* Mutant Zebrafish Do Not Recapitulate Morpholino-Induced Vascular and Haematopoietic Phenotypes. *PLoS One* 10, e0141611.
- Prykhozhiy, S.V., Fuller, C., Steele, S.L., Veinotte, C.J., Razaghi, B., Robitaille, J.M., McMaster, C.R., Shlien, A., Malkin, D., Berman, J.N., 2018. Optimized knock-in of point mutations in zebrafish using CRISPR/Cas9. *Nucleic Acids Res*.
- Robu, M.E., Larson, J.D., Nasevicius, A., Beiraghi, S., Brenner, C., Farber, S.A., Ekker, S.C., 2007. p53 activation by knockdown technologies. *PLoS Genet* 3, e78.

- Rossi, A., Kontarakis, Z., Gerri, C., Nolte, H., Holper, S., Kruger, M., Stainier, D.Y., 2015. Genetic compensation induced by deleterious mutations but not gene knockdowns. *Nature* 524, 230-233.
- Smith, A.T., Sack, G.H., Jr., Taylor, G.J., 1979. Holt-Oram syndrome. *J Pediatr* 95, 538-543.
- Smits, A.H., Ziebell, F., Joberty, G., Zinn, N., Mueller, W.F., Clauder-Munster, S., Eberhard, D., Falth Savitski, M., Grandi, P., Jakob, P., Michon, A.M., Sun, H., Tessmer, K., Burckstummer, T., Bantscheff, M., Steinmetz, L.M., Drewes, G., Huber, W., 2019. Biological plasticity rescues target activity in CRISPR knock outs. *Nat Methods*.
- Stainier, D.Y.R., Raz, E., Lawson, N.D., Ekker, S.C., Burdine, R.D., Eisen, J.S., Ingham, P.W., Schulte-Merker, S., Yelon, D., Weinstein, B.M., Mullins, M.C., Wilson, S.W., Ramakrishnan, L., Amacher, S.L., Neuhaus, S.C.F., Meng, A., Mochizuki, N., Panula, P., Moens, C.B., 2017. Guidelines for morpholino use in zebrafish. *PLoS Genet* 13, e1007000.
- Valenti, F., Ibeti, J., Komiya, Y., Baxter, M., Lucchese, A.M., Derstine, L., Covaciu, C., Rizzo, V., Vento, R., Russo, G., Macaluso, M., Cotelli, F., Castiglia, D., Gottardi, C.J., Habas, R., Giordano, A., Bellipanni, G., 2015. The increase in maternal expression of *axin1* and *axin2* contribute to the zebrafish mutant *ichabod* ventralized phenotype. *J Cell Biochem* 116, 418-430.
- Varga, M., Maegawa, S., Bellipanni, G., Weinberg, E.S., 2007. Chordin expression, mediated by Nodal and FGF signaling, is restricted by redundant function of two beta-catenins in the zebrafish embryo. *Mech Dev* 124, 775-791.
- Zhou, F., Leder, P., Zuniga, A., Dettenhofer, M., 2009. Formin1 disruption confers oligodactylysm and alters Bmp signaling. *Hum Mol Genet* 18, 2472-2482.
- Zuniga, A., Laurent, F., Lopez-Rios, J., Klasen, C., Matt, N., Zeller, R., 2012. Conserved cis-regulatory regions in a large genomic landscape control SHH and BMP-regulated Gremlin1 expression in mouse limb buds. *BMC Dev Biol* 12, 23.


A




B




C




D



E



F









A *ctnnb2*-M01 3'-CAAACcTTCAGCGAGTCCGATTTC-5'


5'-TTCTCTGCAGGTTTGaAAGTCGCTCAGGCTAAAGGATTGACGCAACGATG-3'

intron 1 -><- exon 2 Bpu10I M ...

5'-GCAGGTTTGAAAGTCGCTC-> *ctnnb2deM01*


5'-gGAAAGTCGCTCAGGCTAA-> *ctnnb2deM02*





C

	TIDE efficiency score	TIDE most prominent indels	ICE efficiency score	ICE most prominent indels
tbx5adeMO1	16.9%	(+1) 5.2%, (-7) 3.0%, (-1) 2.4%	7%	(+1) 4.0%, (-12) 2.0%, (-7), 1.0%
tbx5adeMO2	29.9%	(-3) 8.7%, (-7) 6.7%, (-4) 2.8%	11%	(-3) 4.0%, (-7) 3.0%



C

	TIDE efficiency score	TIDE most prominent indels	ICE efficiency score	ICE most prominent indels
ctnnb2 deMO1	17.2%	(-4) 7.0%, (-5) 2.1%, (-2) 2.0%	5%	(-4) 5.0%
ctnnb2 deMO2	4.4%	(-4) 1.3%, (-6) 0.7%, (-8) 0.6%	0%	---